Coleman M D, Tingle M D, Hussain F, Storr R C, Park B K
Department of Pharmacology and Therapeutics, University of Liverpool, UK.
J Pharm Pharmacol. 1991 Nov;43(11):779-84. doi: 10.1111/j.2042-7158.1991.tb03481.x.
With microsomes prepared from a single human liver, 4,4'-diaminodiphenyl sulphone (DDS), 4-acetyl-4-aminodiphenyl sulphone (MADDS), 4-acetyl-4-aminodiphenyl thioether (MADDT) and 4,4'-diacetyldiphenyl thioether (DADDT) caused significantly greater methaemoglobin formation compared with control. In-vitro in the rat, the pattern of toxicity was slightly different:DADDT was not haemotoxic, whilst 3,4'-diaminodiphenyl sulphone (3,4'DDS) and 3,3'-diaminodiphenyl sulphone (3,3'DDS) as well as DDS, MADDS and MADDT were significantly greater than control. 4,4' Acetyl diphenyl sulphone (DADDS), 4,4' diaminodiphenyl thioether (DDT), 4,4'-diaminodiphenyl ether (DDE) and 4,4' diaminooctofluorodiphenyl sulphone (F8DDS) did not cause significant methaemoglobinaemia in either human or rat liver microsomes. DDS, MADDS, and MADDT were not significantly different in haemotoxicity generation in-vitro in the presence of human microsomes. In the rat in-vitro, DDS, MADDS, and 3,4'DDS did not differ significantly in red cell toxicity, and were the most potent methaemoglobin formers. The 3,3'DDS and MADDT derivatives were both significantly less toxic compared with DDS. None of the compounds tested caused haemoglobin oxidation in the absence of NADPH in-vitro. In the whole rat, DDS, MADDS and MADDT caused significantly higher levels of methaemoglobin compared with control. None of the remaining compounds caused methaemoglobin formation which was significantly greater than control. DDS and MADDS were the most potent methaemoglobin formers tested, in-vivo and in-vitro.(ABSTRACT TRUNCATED AT 250 WORDS)
使用从单个供体肝脏制备的微粒体,与对照组相比,4,4'-二氨基二苯砜(DDS)、4-乙酰基-4-氨基二苯砜(MADDS)、4-乙酰基-4-氨基二苯硫醚(MADDT)和4,4'-二乙酰基二苯硫醚(DADDT)导致高铁血红蛋白形成显著增加。在大鼠体外实验中,毒性模式略有不同:DADDT没有血液毒性,而3,4'-二氨基二苯砜(3,4'DDS)、3,3'-二氨基二苯砜(3,3'DDS)以及DDS、MADDS和MADDT显著高于对照组。4,4'-乙酰基二苯砜(DADDS)、4,4'-二氨基二苯硫醚(DDT)、4,4'-二氨基二苯醚(DDE)和4,4'-二氨基八氟二苯砜(F8DDS)在人或大鼠肝脏微粒体中均未引起显著的高铁血红蛋白血症。在存在人微粒体的体外实验中,DDS、MADDS和MADDT在产生血液毒性方面无显著差异。在大鼠体外实验中,DDS、MADDS和3,4'DDS在红细胞毒性方面无显著差异,且是最有效的高铁血红蛋白形成剂。3,3'DDS和MADDT衍生物的毒性均显著低于DDS。在体外无NADPH的情况下,所测试的化合物均未引起血红蛋白氧化。在整个大鼠体内,与对照组相比,DDS、MADDS和MADDT导致的高铁血红蛋白水平显著更高。其余化合物均未导致高铁血红蛋白形成显著高于对照组。DDS和MADDS是体内和体外实验中测试的最有效的高铁血红蛋白形成剂。(摘要截短至250字)